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Glycosaminoglycans prevent morphological renal alterations and albu-
minuna in diabetic rats. Abnormal glycosaminoglycan metabolism is
involved in the onset of anatomo-functional derangements in diabetic
nephropathy, and determines the loss of glomerular basement mem-
brane anionic charges leading to albuminuria. Glycosaminoglycan ad-
ministration was shown to increase the negative electrical potential of
the vessel wall, inhibit mesangial cell proliferation, which is an anatom-
ical hallmark of diabetic nephropathy, and slow down the progression
to uremia in subtotally nephrectomized rats, a model that shares some
pathogenetic key events with diabetic nephropathy. Based on these
considerations, we verified the effect of exogenous glycosaminoglycans
on renal involvement in streptozotocin diabetic rats. Long-term admin-
istration of two glycosaminoglycans (low-molecular weight heparin and
dermatan sulphate) prevented glomerular basement membrane thicken-
ing, glomerular anionic charge reduction, as well as the onset of
albuminuria without affecting glomerular filtration rate and metabolic
control of the disease. Our data demonstrate that the long-term admin-
istration of glycosaminoglycans has a favorable effect on morphological
and functional renal abnormalities in diabetic rats.
Diabetic nephropathy, one of the major long-term complica-
tions of diabetes mellitus, develops in 30 to 40 percent of type
1 diabetic patients, and terminal renal failure occurs within
seven years after onset of the renal disease [1—3].
The anatomical hallmarks of this metabolic nephropathy
include glomerular basement membrane (GBM) thickening, and
mesangial expansion with hyalinosis both in the mesangium and
in the capillary lumen. The very first clinical marker of unfa-
vorable renal involvement seems to be the so-called "microal-
buminuria" [4], which is commonly considered hemodynamic
in origin [5] and/or due to a biochemical derangement in GBM
composition leading to an abnormal charge permselectivity
[6—8]. The morphological basis of the latter is the reduction in
glomerular charge density [9—111 consequent to non-enzymatic
glycosylation of the various GBM proteins [12], or to a glycos-
aminoglycan (GAG) metabolism disorder leading to reduced
heparan sulphate content or sulfation [13—15].
It was shown that some GAGs inhibit mesangial cell prolif-
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eration both in vitro [16] and in vivo [17, 18], and exert an
antimitogenic effect on glomerular epithelial cells [19] involved
in GBM heparan sulphate synthesis [20]. In addition, GAG
administration increases the negative electrical potential of the
vessel wall [21], and slows down the progression to uremia in
rats with subtotal renal ablation [22—24], an experimental model
that shares some pathogenetic key events with diabetic
nephropathy [5]. These observations make GAGs good candi-
dates for preventing nephropathy in diabetes. This study eval-
uated the effect of exogenous GAGs on renal derangement in
streptozotocin-induced diabetic rats.
Methods
Diabetes was induced in 45 male Sprague-Dawley rats
(Charles River, Como, Italy) aged six to seven weeks by i.v.
administration of 35 mg/kg body weight streptozotocin (STZ;
Sigma Chemical Co., St. Louis, Missouri, USA). Fifteen age-
matched male rats were used as controls. One week later
diabetic rats were randomly allocated in three groups, one of
which started to receive low-molecular weight heparin
(LMWH; Fluxum, Alfa Wassermann SpA, Bologna, Italy) at 6
mg/kg body wt/day s.c., and another was given dermatan
sulphate (DS; Desmin 370, Alfa Wassermann SpA) at 15 mg/kg
body wt/day s.c. Regarding the sulphate/carboxylic ratio the
two drugs were characterized with a potentiometric titration
method [25]. Ratios were 2.5/1 and 1.1/1, respectively; since
GAG dimer has only one carboxylic group, these ratios are an
index of charge density of LMWH and DS. The selected
dosages were based on equivalence for antithrombotic activity
ED5O. The remaining 15 STZ treated rats (STZ), and controls
(C) received 1 ml/day saline solution s.c. Drugs and saline were
injected five days weekly for eight months. Throughout the
study, all rat groups were fed a diet containing 20% protein
(Altromin-R, Rieper, Bolzano, Italy). Diabetes mellitus was
successfully induced in all STZ treated rats. No insulin treat-
ment was given. During the eight months follow-up, one rat in
both the C and DS groups, and two rats in both the STZ and
LMWH groups died from infectious diseases (bronchopneu-
monitis, multiple abscesses). No rats had hemorrhagic disor-
ders.
At the end of the eight month period, the rats were weighed
and transferred to individual metabolic cages for 24 hours,
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Table 1. The evaluated parameters at the end of the experiment in control rats (C), in diabetic rats (STZ), and in diabetic rats treated with a
low molecular weight heparin (LMWH), or with dermatan sulphate (DS)
C STZ LMWH DS
Body weight g 694.5 17.2 380.2 11.9 378.8 12.7 3614 18.5
Glycemia mg/dl 98.4 3.9 537.0 18.7 590,6 19.0 561.0 27.4
GHb % 2.39 0.03 5.47 0.07 5.70 0.16 5.49 0.16
GFR mI/mm/kg body Wta 7.62 0.69 14.44 1.64 13.70 2.23 13.85 1.41
Albuminuria mg/24 hra 0.36 1.24 1.89 1.17 0.39 1.20 0.43 1.15
GBM thickness nma 235.57 1.05 346.19 1.11 221.85 1.08 260.08 1.06
GBM charge density 39.25 1.39 23.07 1.66 42.21 1.73 36.46 1.99
points/1000 nm
Mean SEM
a Variables are reported for simplicity in linear scale. Therefore, the SCM of log-transformed variables has to be back-transformed for confidence
limits.
Fig. 1. Albuminuria in control rats (C), in diabetic rats (STZ), and in
diabetic rats treated with a low molecular weight heparin (LMWH), or
with dermatan sulphate (DS). Logarithmic transformed values are







Fig. 3. Anionic charge density in the glomerular basement membrane
in control rats (C), in diabetic rats (STZ), and in diabetic rats treated
with a low molecular weight heparin (LMWH), or with dermatan
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p < 0.0001 P < 0.0001 glycated hemoglobin (GHb) with a Boehringer Mannheim
------- ::-:::: P-NS GmbH Kit (Mannheim, Germany). Albuminuria was assayed
by the simple immunodiffusion technique [26] using a rabbit
anti-rat albumin antiserum and rat albumin as standard (USB
Immunochemicals, Cleveland, Ohio, USA). Subsequently, all
rats, except three randomly-selected animals from each group,
-+— 4...
,
were sacrificed by exsanguination following pentobarbital an-
esthesia.
Twenty-four to 30 hours after the last s.c. drug/placebo
administration, the three spared animals/group were instead
perfused in vivo with a solution containing 0.2 percent ruthe-
nium red (RR) (Carlo Erba, Milano, Italy) in Karnovsky's
aldehyde fixative at a flow rate of 4 to 5 ml/min, with perfusion
pressure ranging from 90 to 100 mm Hg for five minutes as
—
C LMWH DS previously described [27]. The animals were then killed as
above. Small tissue blocks were cut from the renal cortex of the
FIg. 2. Glomerular basement membrane thickness in control rats (C),
in diabetic rats (STZ), and in diabetic rats treated with a low molecular upper pole and fixed for 20 hours at room temperature in the
weight heparin (LMWH), or with dermatan sulphate (DS). Logarithmic same RR-fixative mixture that had been used for perfusion.
transformed values are given. F = 10.8; P < 0.0001. After appropriate rinsing and postfixation, the specimens were
dehydrated in ascending alcohols, and embedded in Epon 810.
Ultrathin sections were cut, lightly counterstained with uranyl
during which time urine was collected. Blood was withdrawn 24 acetate and examined at the electron microscope (Siemens 101).
hours after the last drug administration. Creatinine was evalu- Morphometric analysis was carried out in the blind on four to
ated by the creatininase method; glucose by glucose oxidase; six randomly selected GBM areas (final magnification x36,000)
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Fig. 5. Glomerular basement membrane in diabetic rats (final magnification X32,000).
Fig. 4. Glomerular basement membrane in control rats (final magnification x32 000).
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Fig. 6. Glomerular basement membrane in diabetic rats treated with LMWH (final magn(tication X32,000).
in each case. GBM width () was evaluated according to Weibel
[28], using the following expression:
= 2d x [PI('a + SIb)].
Briefly, a simple square grid system (A 100) was superimposed
on the photographs. P (points falling onto barrier profiles), 'a'
and 'b (intersections with the trace of the reference surface on
both its binding surface) were then calculated; d (distance of
test lines) was calibrated at 175 nm. By means of a semiauto-
matic image analyzer (Ibas Kontron), the length of the outer
GBM surface and the number of anionic charges stained by RR
in the lamina rara externa were determined. Values were
expressed per 1000 nm of GBM linear length. All evaluations
were carried out twice, and a very good straight correlation
between the two series was obtained (GBM width, r = 0.99;
anionic charge density, r = 0.95).
Statistical analysis
We used one-way analysis of variance (ANOVA) for glomer-
ular filtration rate (GFR; creatinine clearance) and albuminuria,
and two-way ANOVA for morphometnc parameters. The latter
enabled evaluation of the effect of both treatment and animal
variability on charge density and GBM thickness. The 7D
program of the BMDP statistical package [29] was used for
calculation. Logarithmic transformation of GBM thickness,
GFR and albuminuria were used in ANOVA in order to reduce
positive skewing and equalize the variances of some experimen-
tal groups. Alter ANOVA, specific hypothesis regarding differ-
ences in morphometric parameters among groups were tested
by contrasts (linear combinations of means). Bonferroni's test
for multiple comparisons was applied to GFR and albuminuria
values. The 6D program [29] was employed for linear correla-
tion analysis. Analysis of covariance was not performed on
morphometric values since charge density was linearly corre-
lated with GBM thickness only in the diabetic group.
Results
Mean values of the parameters concerning metabolic control,
renal morphometry and functions are reported in the table.
Metabolic control, explored with glycemia, body weight and
GHb, was similar in the three diabetic groups. All the diabetic
rats were hyperfiltering, compared to healthy control rats (F =
5.40; P = 0.0039), but no significant difference emerged be-
tween the three diabetic groups.
Urinary albumin excretion was markedly increased in un-
treated diabetic rats (F = 24.8; P < 0.0001); no significant
difference between controls and LMWH as well as DS diabetic
rats, nor between LMWH and DS animals was found (Table 1,
Fig. 1).
Observation at the light and electron microscope revealed the
typical renal lesions described in experimental diabetes mellitus
in the untreated diabetic rats. These findings, and in particular
GBM thickening, charge density loss, and foot process fusion,
were observed to a lesser extent in the treated diabetic animals
(Figs. 4, 5, 6, and 7).
I
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Fig. 7. Glomerular basement membrane in diabetic rats treated with DS (final magn(flcation x32,000).
GBM thickness differed among, but not within groups (F =
10.8, P < 0.0001, and F = 1.67, NS, respectively). GBM
thickness was greater in diabetic rats compared to control
animals (P < 0.001), and both LMWH (P < 0.0001) and DS (P
0.002) groups, but no difference emerged between control,
LMWH and DS groups (Table 1 and Figs. 2, 4, 5, 6, 7).
GBM charge density differed among, but not within groups (F
= 30.0, P < 0.0001, and F = 2.2, NS, respectively). Charge
density in diabetic rats was lower than in control animals (P <
0.0001), as well as in LMWH (P < 0.0001) and DS groups (P <
0.COOl). It was also significantly higher in the LMWH compared
to the DS group (P = 0.005; Table 1 and Figs. 3, 4, 5, 6, 7).
In the diabetic group, GBM charge density was significantly
correlated with thickness (r =
—0.702; P < 0.011). In no other
group were significant correlations found between these vana-
bles.
Discussion
This study demonstrates that the administration of gly-
cosaminoglycans, such as LMW heparin and DS, in diabetic
rats is capable of preventing both GBM thickening (Fig. 2) and
a reduction in anionic charge density in the GBM (Fig. 3), and
is able to maintain urinary excretion of albumin at normal levels
(Fig. 1) without affecting the metabolic control of the disease.
Rasch had previously demonstrated that a sufficiently good
control of glycemia by insulin administration was capable of
preventing renal lesions in diabetic rats [30, 31]. However, in
our animals no insulin treatment was given, so metabolic
control was poor; thus, the good results obtained were depen-
dent only on GAG treatment.
These findings were not completely unexpected, as studies
with other experimental models of nephropathy in which
mesangial expansion also occurs [17, 18] reported favorable
histological and clinical effects for these agents.
In its early stages diabetic nephropathy is characterized by a
thickening of the GBM and a reduction in heparan sulphate-
related anionic sites in the GBM itself [9—111. These morpho-
logical abnormalities probably follow a derangement in matrix
synthesis by mesangial and glomerular epithelial cells, due to
diabetes [8, 13—15]. The appearance of microalbuminuria, the
very first clinical marker of diabetic nephropathy in humans, at
least in part would be secondary to these morphological and
biochemical disturbances [8]. That drugs capable of preventing
the reduction in GBM charge density without affecting glomer-
ular filtration rate, such as LMWH and DS, also prevent the
appearance of albuminuria (Fig. 1), lends experimental support
to the above hypothesis regarding the origin of microalbumin-
uria in diabetes. It concomitantly raises some doubt about the
role of modifications in glomerular hemodynamics as the basis
for drug-induced amelioration of the glomerular damage. This
conclusion agrees with previous observations in the experimen-
tal model of subtotal renal ablation [32].
We must admit that since coagulative mechanisms seem





290 Gambaro et a!: Glycosaminoglycans prevent nephropathy in diabetic rats
activity of LMWH and DS is most likely independent of their
anticoagulant properties. Furthermore, the two drugs have
completely different targets in the coagulation cascade. In line
with these considerations is strong evidence that anticoagula-
tion was not needed for the expression of the GAG protective
effect in other experimental models of nephropathy. Diamond
and Karnovsky [181 demonstrated that chronic aminoglucoside
nephrosis, which is characterized by mesangial proliferation, is
prevented (and mesangial hypercellularity also) by non-antico-
agulant heparin. In the quite different model of subtotal ne-
phrectomy, in which mesangial hypercellularity still occurs,
Purkerson, Tollefsen and Klahr [24] demonstrated that chemi-
cally transformed heparin devoid of anticoagulant activity ame-
liorates the progression of renal disease in the same way as
anticoagulant heparin. Purkerson et al had previously demon-
strated that renal disease in subtotally nephrectomized rats was
prevented by heparin, but not by other anticoagulant drugs such
as coumadin [33], thus supporting, for the first time, the idea
that the favorable activity of heparin on renal disease resides on
different targets, other than the coagulation cascade.
The chemical structure of the two drugs differs concerning
the disaccharide unit and the sulphate/carboxylic ratio, and this
seems to be important because LMWH and DS exert different
effects on glomerular charge density (Fig. 3). This is in agree-
ment with previous in vitro and in vivo observations [16, 18,
24].
We have no data regarding non-enzymatic glycation of GBM
proteins, but, considering that it is somehow mirrored by
hemoglobin glycation, we believe that the positive effects
exerted by GAGs do not depend on an effect on protein
glycation because GHb was not different between the three
diabetic groups.
Olson's hypothesis, that the protective effect exerted by
GAGs is simply due to a mechanical restoration of glomerular
charges by these polyanionic compounds [23], seems insuffi-
cient to explain the full picture of our experimental model. In
fact, the favorable effect we observed was still present after 24
to 30 hours after the last drug administration; this interval is
much longer than would be expected if the administered GAG
stuck to the GBM, because the disappearance of injected GAGs
from vessels and kidney takes much less time [34]. The possi-
bility exists that GAGs bind to GBM proteins, laminin or
fibronectin, which have binding sites for heparan sulphate [35].
However, since these binding sites have very high specificity
for heparan sulphate and heparin, this mechanism, as a possible
explanation of the increased anionic charge density after GAG
treatment, might be true only for LMWH, but not for DS.
Moreover, the morphological effect exerted by GAGs was on
the visceral side of the glomerular sieve, and not on the
endothelium where such restoration of anionic charges had
been previously demonstrated [21]. Finally, the beneficial effect
not only involved the charge density of the GBM, but, more
interestingly, the thickness of the membrane itself as well (Fig.
2). This suggests a more complex GAG effect on the synthesis
of matrixlGBM constituents by glomerular cells, leading to the
correction of some biochemical or cell function abnormalities
associated pathogenetically with diabetic nephropathy. This
hypothesis is supported by in vitro findings that exogenous
heparin and other GAGs or endogenous heparan sulphate-like
molecules, inhibit glomerular epithelial and mesangial cell pro-
liferation [16, 19], and in very similar cells, such as vascular
smooth muscular cells, influence the synthesis and composition
of extracellular matrix both in vitro and in vivo [36]. Based on
this type of observation, Coffey and Karnovsky [17] proposed a
scenario in which exogenous heparin exerts in vivo its benefi-
cial effect on the progression of some glomerular diseases by
replacing lost endogenous heparan sulphate, and consequently
restoring the normal proliferation and protidosynthesis of gb-
merular cells.
In conclusion, our data demonstrate that long-term adminis-
tration of GAGs has a favorable effect on morphological and
functional renal abnormalities in diabetic rats, and thus suggests
the potential usefulness of this class of molecules in the
prevention of diabetic nephropathy. Moreover, they indirectly
support the hypothesis that the derangement in GAG metabo-
lism has a pathogenetic role in the onset of diabetic nephrop-
athy.
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